Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer
{{output}}
Trastuzumab is currently a key targeted drug for HER2-positive gastric cancer (GC), but there are common problems of drug resistance and cardiotoxicity in clinical treatment, resulting in poor therapeutic effects. Exosomes are natural nanocarriers for drug del... ...